<![CDATA[Pirtobrutinib Combo Boosts PFS in Previously Treated CLL/SLL]]>

Phase 3positivePirtobrutinibVenetoclaxRituximabPositive

AI Analysis

Summary

Pirtobrutinib combined with venetoclax and rituximab demonstrated a 45% reduction in progression or death risk in previously treated CLL/SLL patients in the phase 3 BRUIN CLL-322 trial, showing positive efficacy data.

Clinical Trial Data

Phase

Primary Endpoint

Met

Outcome Details

Pirtobrutinib plus venetoclax/rituximab reduced risk of progression or death by 45% in previously treated CLL/SLL patients

Importance:7/10

Sentiment:

0.85

Phase 3CLL/SLLCombination TherapyPositive DataBRUIN CLL-322

Related Companies

$LLY

Read the original article

Published by Cancer Network on August 3, 2026 2:30 PM

Read Original